Mindfulness-Music Intervention in Reducing Anxiety and Stress in Adolescents and Young Adults Receiving Cancer Treatment
- Have a diagnosis of any cancer
- Have begun treatment for cancer and plan to receive active cancer treatment (e.g., radiation, chemotherapy, or oral chemotherapy) over the next eight weeks
- Willingness to participate in all study activities
- Speak/read English
- SPECIAL POPULATIONS: Children (individuals 15 – 17 years old)
- SPECIAL POPULATIONS: Pregnant women
- Prognosis < 3 months
- Self-report inability to physically interact with musical instruments (e.g., hold instruments)
- Documentation of significant hearing impairment (e.g., deaf)
- SPECIAL POPULATIONS: Adults unable to consent
- SPECIAL POPULATIONS: Prisoners
- SPECIAL POPULATIONS: Infants and children (individuals < 15 years old)
I. Determine the feasibility of adolescents and young adults (AYA) recruitment and adherence to a mindfulness-music intervention during cancer treatment.
Ia. Explore AYAs’ perspectives of acceptability and satisfaction with participation in a mindfulness-music intervention during cancer treatment.
Ib. Examine potential participants’ reasons for declining participation in a mindfulness-music intervention during cancer treatment.
II. Evaluate the impact of a mindfulness-music therapy intervention to reduce anxiety and stress in AYAs receiving cancer treatment.
IIa. Explore the impact of a mindfulness-music therapy intervention to improve fatigue, depression, social/role functioning, pain intensity, pain interference, and sleep-disturbance.
III. Explore demographic and clinical factors that moderate the impact of a mindfulness-music therapy intervention on anxiety and stress severity in AYAs receiving cancer treatment.
IV. Examine the internal consistency reliability and content validity of the Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a and Perceived Stress Scale in adolescents and young adults receiving cancer treatment.
Patients attend 4 in-person or Zoom music therapy sessions over 45 minutes each over 12 weeks.
Trial Phase Phase NA
Trial Type Supportive care
Dana-Farber Harvard Cancer Center
Robert J Knoerl
- Primary ID 18-341
- Secondary IDs NCI-2018-03554
- Clinicaltrials.gov ID NCT03709225